BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that the company was honored by the National Organization for Rare Disorders (NORD) for the FDA approval of Gattex® (teduglutide [rDNA origin]) for injection, which is indicated for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. SBS is a rare and potentially fatal gastrointestinal disorder in which patients are unable to absorb enough nutrients and fluids through the intestine from the foods they eat.